WeVote
Log In

Bill

Bill

HB 391

Medical cannabis program; product labels, delivery.

2026 Regular Session Introduced by Alex Askew

HB 391 establishes labeling and delivery standards for Virginia's medical cannabis program to enhance patient safety and prevent unauthorized distribution.

Governor's recommendation received by House
0
WeVote Research Nonpartisan
Bill Summary · HB 391

Legislative bill overview

HB 391 modifies Virginia's medical cannabis program by establishing new requirements for product labeling and delivery mechanisms. The bill has already passed the House with unanimous support (99-0) and is currently under committee review in the Senate.

Why is this important

Medical cannabis labeling and delivery standards directly affect patient safety, product traceability, and program integrity. Clear labeling helps patients understand dosage and ingredients, while standardized delivery procedures reduce unauthorized distribution and ensure the program operates as intended for qualifying patients.

Potential points of contention

  • Labeling specificity: Disagreement may arise over how detailed labels must be regarding potency, cannabinoid content, and health warnings—balancing patient information needs against manufacturer compliance costs
  • Delivery restrictions: The bill likely addresses who can deliver products and under what conditions; some may argue restrictions are too rigid (limiting patient access) while others contend they're insufficiently strict (enabling black market competition)
  • Implementation costs: Compliance expenses for dispensaries and producers may be disputed, particularly regarding label redesigns and delivery system modifications for smaller operators

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.